Y-Prime LLC
, an enterprise consulting and eClinical products company, has established a systems integration partnership with
Veeva Systems
, a company in cloud-based business solutions for the global life sciences industry.
Together, the companies aim to provide global life sciences organizations with the tools to establish a content management solution as well as the ability to facilitate a smooth migration of legacy ECM platforms, such as Documentum and FirstDoc, to Veeva Vault in the cloud.
"Y-Prime has deep domain expertise in document management solutions..." explains Dan Glass, vice president of Enterprise Content Management at Y-Prime. "As global life sciences companies seek to migrate from expensive, legacy systems such as Documentum, our partnership with Veeva offers a path that integrates the change management, technical implementation and training expertise that will ensure a successful transition to the Vault Enterprise applications. For those companies that have not invested in ECM as yet," Dan continues, "our deep domain experience will play a significant role in helping companies to develop a strategy to fully realize the benefits of Vault Enterprise."
Veeva Systems recently announced Vault Enterprise, the first cloud-based suite of content management applications developed specifically for the global life sciences industry. Spanning every major part of a life sciences company - from R&D to clinical trials to manufacturing, medical communications and marketing - Vault Enterprise aims to give the pharmaceutical, biotechnology and medical products companies the ability to deploy a single technology solution globally. The results are faster implementations, dramatic cost savings and reduced regulatory risk.
"Y-Prime's knowledge of the legacy environments operating in this industry makes them well-suited to assist our customers in their moves to the cloud," says Jennifer Goldsmith, vice president of strategy, Veeva Vault at Veeva Systems. "Working together, we will help our clients reduce time to market and ensure regulatory compliance through the implementations of Vault Enterprise."
Global life sciences companies engage Y-Prime's ECM and eCTD practice team to develop transformative strategies combined with technical expertise in cloud transformation, externalization and harmonization as well as business process consulting. Y-Prime also provides eClinical systems consulting as well as a suite of cloud-based eClinical solutions; Prime IWRS, Prime eMVR, Prime ePRO and Prime Publisher.
Please visit Veeva (Booth 201) and Y-Prime (Booth 311) at the Drug Industry Association's EDM and ERS/eCTD Conference October 8-11 at the Hilton Baltimore.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.